CSWM
BMRN icon

Cassady Schiller Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cassady Schiller Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$854 Buy
+13
New +$871 ﹤0.01% 835
2023
Q2 		– Sell
-5
Closed -$486 – 470
2023
Q1 		$486 Buy
+5
New +$518 ﹤0.01% 433

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Cassady Schiller Wealth Management's BMRN Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q4 2024: 13 shares worth $854. The stake represents ﹤0.01% of the portfolio and ranks #835 among its holdings. This is a return to the name: Cassady Schiller Wealth Management previously reported a position in BMRN as recently as Q1 2023.

Cassady Schiller Wealth Management first reported a position in BMRN in Q1 2023 and has held it in 2 quarters since. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

  • Cassady Schiller Wealth Management held 13 shares of BioMarin Pharmaceuticals worth $854 as of Q4 2024.
  • BioMarin Pharmaceuticals was a new Cassady Schiller Wealth Management position in Q4 2024.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #835 holding.
  • Cassady Schiller Wealth Management first reported a position in BioMarin Pharmaceuticals in Q1 2023 and has held it in 2 quarters since.
  • 543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.